Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 + Exemestane + Everolimus in HR+/HER2- Breast Cancer with Bone Metastases
NCT02258451Phase 2Completed
- Sponsor
- Bayer
- Start
- Jun 2015
- Primary completion
- Jan 2020
- Modality
- Radiopharmaceutical
- Countries
- 17
01
Overview
A Phase 2 trial of radium-223 dichloride in breast cancer, sponsored by Bayer. Started Jun 2015; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02258451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02258451.